HROWNasdaqPharmaceutical PreparationsFiscal year ends December 31
HARROW, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 10, 2026
$27.68+0.40 (+1.47%)
Close on Oct 19, 2026
- Market cap
- $1.03B
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
57.4%
22M of 37M shares
Institutional holders
223
41 new, 34 sold out
Net institutional buying
0M
In Q2 2026
Insider trades, 12 months
4 buys · 7 sales
Net sold $9.17M
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Mark L. Baum | 4,056,962 | 10.69% | 13D (active) amendment | Apr 3, 2025 |
| Private Capital Management, LLC ( ) | 3,630,496 | 10.34% | 13G (passive) | Dec 31, 2023 |
| Opaleye Management Inc. | 2,832,230 | 7.61% | 13G (passive) amendment | Mar 31, 2026 |
| James Silverman | 2,400,000 | 6.44% | 13G (passive) amendment | Jun 30, 2026 |
| BlackRock, Inc. | 2,220,538 | 6.30% | 13G (passive) | Dec 31, 2023 |
| Daniel Kaufman | 1,878,000 | 5.04% | 13G (passive) | Mar 10, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of HROW | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| BlackRock, Inc. | 2,740,117 | 7.31% | $116.37M | +187,358 | 0.00% |
| Opaleye Management Inc. | 2,400,000 | 6.40% | $101.93M | −432,230 | 9.23% |
| Private Capital Management, LLC | 1,598,770 | 4.26% | $67.90M | +36,770 | 5.98% |
| Vanguard Capital Management LLC | 1,417,212 | 3.78% | $60.19M | +14,156 | 0.00% |
| Deep Track Capital, LP | 969,000 | 2.58% | $41.15M | New | 0.60% |
| State Street Corp | 939,888 | 2.51% | $39.92M | +84,841 | 0.00% |
| Geode Capital Management, LLC | 905,560 | 2.42% | $38.47M | +53,526 | 0.00% |
| Bamco Inc /Ny/ | 809,350 | 2.16% | $34.37M | New | 0.05% |
| Dimensional Fund Advisors LP | 667,036 | 1.78% | $28.33M | +87,516 | 0.01% |
| Jupiter Topco LLC | 579,127 | 1.54% | $24.60M | New | 0.01% |
| Divisadero Street Capital Management, LP | 439,155 | 1.17% | $18.65M | New | 0.42% |
| Rice Hall James & Associates, LLC | 387,545 | 1.03% | $16.46M | +19,368 | 0.80% |
| Marshall Wace, Llp | 369,435 | 0.99% | $15.69M | −275,483 | 0.01% |
| Citadel Advisors LLC | 359,874 | 0.96% | $15.28M | +138,616 | 0.00% |
| Northern Trust Corp | 323,206 | 0.86% | $13.73M | +26,341 | 0.00% |
| Schonfeld Strategic Advisors LLC | 319,625 | 0.85% | $13.57M | New | 0.05% |
| Vanguard Portfolio Management LLC | 318,610 | 0.85% | $13.53M | +29,735 | 0.00% |
| Charles Schwab Investment Management Inc | 273,696 | 0.73% | $11.62M | +3,160 | 0.00% |
| Vanguard Fiduciary Trust Co | 235,418 | 0.63% | $10.00M | +7,797 | 0.00% |
| Westside Investment Management, Inc. | 224,051 | 0.60% | $9.52M | +38,125 | 1.25% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 223 | 22M | 57.4% | 41 / 81 | 65 / 34 | 5M | 5M |
| Q1 2026 | 219 | 21M | 57.3% | 44 / 67 | 77 / 33 | 5M | 3M |
| Q4 2025 | 215 | 22M | 59.3% | 49 / 65 | 66 / 30 | 3M | 2M |
| Q3 2025 | 197 | 21M | 56.9% | 56 / 53 | 60 / 18 | 3M | 3M |
| Q2 2025 | 160 | 21M | 56.2% | 29 / 65 | 43 / 25 | 2M | 2M |
| Q1 2025 | 156 | 21M | 56.3% | 23 / 51 | 59 / 30 | 3M | 2M |
| Q4 2024 | 165 | 21M | 55.8% | 38 / 52 | 52 / 31 | 2M | 3M |
| Q3 2024 | 159 | 21M | 56.6% | 60 / 39 | 42 / 9 | 7M | 3M |
| Q2 2024 | 110 | 19M | 51.3% | 21 / 42 | 30 / 22 | 2M | 5M |
| Q1 2024 | 112 | 23M | 60.8% | 15 / 38 | 38 / 15 | 2M | 3M |
| Q4 2023 | 113 | 24M | 65.3% | 13 / 41 | 36 / 26 | 4M | 5M |
| Q3 2023 | 128 | 25M | 66.8% | 24 / 52 | 29 / 8 | 5M | 3M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of HROW | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 1,001,445 | 2.67% | $42.53M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 842,000 | 2.25% | $35.76M | 0.04% | Jun 30, 2026 |
| Baron Discovery Fund | 576,069 | 1.54% | $24.47M | 1.34% | Jun 30, 2026 |
| Janus Henderson Venture Fund | 468,451 | 1.25% | $19.90M | 0.55% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 383,781 | 1.02% | $16.30M | 0.02% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 353,740 | 0.94% | $13.71M | 0.04% | Jul 31, 2026 |
| iShares Russell 2000 Growth ETF | 298,900 | 0.80% | $12.69M | 0.08% | Jun 30, 2026 |
| State Street(R) SPDR(R) S&P(R) Pharmaceuticals ETF | 182,110 | 0.49% | $7.73M | 1.81% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 170,863 | 0.46% | $6.02M | 0.01% | May 31, 2026 |
| Vanguard Russell 2000 Index Fund | 161,996 | 0.43% | $5.70M | 0.03% | May 31, 2026 |
| Schwab U.S. Small-Cap ETF | 158,672 | 0.42% | $5.59M | 0.02% | May 31, 2026 |
| U.S. Small Cap Portfolio | 148,359 | 0.40% | $5.75M | 0.03% | Jul 31, 2026 |
| Private Capital Management Value Fund | 126,154 | 0.34% | $4.89M | 6.73% | Jul 31, 2026 |
| Dimensional U.S. Small Cap ETF | 125,599 | 0.34% | $4.87M | 0.03% | Jul 31, 2026 |
| JNL Multi-Manager Small Cap Growth Fund | 120,054 | 0.32% | $5.10M | 0.20% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Mark L. Baum | CHIEF EXECUTIVE OFFICER, Director | 3,594,256 | 9.59% | May 15, 2026 |
| Amir Shojaei | CHIEF SCIENTIFIC OFFICER | 0 | – | Aug 17, 2026 |
| Andrew R. Boll | PRESIDENT AND CFO | 814,679 | 2.17% | May 15, 2026 |
| Patrick William Sullivan | CHIEF COMMERCIAL OFFICER | – | – | Feb 2, 2026 |
| Francis William Mullery Jr | CEO, ImprimisRx | – | – | Oct 10, 2025 |
| Randall E. Pollard | CHIEF ACCOUNTING OFFICER | – | – | Sep 9, 2025 |
| John P. Saharek | CEO & President, ImprimisRx | 467,388 | 1.25% | Apr 7, 2025 |
| Lauren P. Silvernail | Director | 1,000 | 0.00% | Jun 22, 2026 |
| Perry J. Sternberg | Director | – | – | Jun 22, 2026 |
| Adrienne L. Graves | Director | 1,000 | 0.00% | Jun 22, 2026 |
| Management Inc. Opaleye | 10% owner | 3,681,428 | 9.82% | Mar 5, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Amir Shojaei CHIEF SCIENTIFIC OFFICER | Aug 14, 2026 | Sale | −11,250 | $40.00 | $450.00K | 0 |
| Amir Shojaei CHIEF SCIENTIFIC OFFICER | Aug 14, 2026 | Option exercise | +11,250 | $35.96 | $404.55K | 11,250 |
| Adrienne L. Graves Director | May 18, 2026 | Buy | +1,000 | $31.07 | $31.07K | 1,000 |
| Lauren P. Silvernail Director | May 18, 2026 | Buy | +1,000 | $31.00 | $31.00K | 1,000 |
| Andrew R. Boll PRESIDENT AND CFO | May 14, 2026 | Buy | +3,500 | $29.90 | $104.65K | 814,679 |
| Mark L. Baum CHIEF EXECUTIVE OFFICER, Director | May 14, 2026 | Buy | +10,000 | $30.20 | $302.00K | 2,996,130 |
| Management Inc. Opaleye 10% owner | Mar 4, 2026 | Sale | −4,263 | $39.67 | $169.11K | 59,428 |
| Management Inc. Opaleye 10% owner | Mar 4, 2026 | Sale | −134,000 | $39.67 | $5.32M | 3,622,000 |
| Management Inc. Opaleye 10% owner | Mar 3, 2026 | Sale | −59,000 | $39.15 | $2.31M | 3,756,000 |
| Management Inc. Opaleye 10% owner | Mar 3, 2026 | Sale | −1,309 | $39.15 | $51.25K | 63,691 |
| Management Inc. Opaleye 10% owner | Feb 27, 2026 | Sale | −5,000 | $54.18 | $270.90K | 65,000 |
| Management Inc. Opaleye 10% owner | Jan 6, 2026 | Sale | −20,000 | $53.35 | $1.07M | 70,000 |
| Mark L. Baum CHIEF EXECUTIVE OFFICER, Director | Dec 12, 2025 | Option exercise | +180,000 | $3.95 | $711.00K | 3,066,124 |
| Mark L. Baum CHIEF EXECUTIVE OFFICER, Director | Dec 12, 2025 | Tax withholding | −79,994 | $47.06 | $3.76M | 2,986,130 |
| Andrew R. Boll PRESIDENT AND CFO | Dec 12, 2025 | Tax withholding | −26,665 | $47.06 | $1.25M | 811,179 |
| Andrew R. Boll PRESIDENT AND CFO | Dec 12, 2025 | Option exercise | +60,000 | $3.95 | $237.00K | 837,844 |
| Mark L. Baum CHIEF EXECUTIVE OFFICER, Director, 10% owner | Jul 21, 2025 | Option exercise | +600,000 | $7.87 | $4.72M | 3,199,462 |
| Mark L. Baum CHIEF EXECUTIVE OFFICER, Director, 10% owner | Jul 21, 2025 | Tax withholding | −313,338 | $37.08 | $11.62M | 2,886,124 |
| Management Inc. Opaleye 10% owner | Jun 10, 2025 | Sale | −15,000 | $30.80 | $462.00K | 90,000 |
| Management Inc. Opaleye 10% owner | Jun 9, 2025 | Sale | −15,204 | $30.37 | $461.75K | 105,000 |
| Management Inc. Opaleye 10% owner | Jun 4, 2025 | Sale | −1,796 | $30.02 | $53.92K | 120,204 |
| Management Inc. Opaleye 10% owner | Jun 3, 2025 | Sale | −3,000 | $30.04 | $90.12K | 122,000 |
| Management Inc. Opaleye 10% owner | May 13, 2025 | Sale | −5,000 | $26.59 | $132.95K | 125,000 |
| Management Inc. Opaleye 10% owner | May 12, 2025 | Sale | −10,000 | $25.90 | $259.00K | 130,000 |
| John P. Saharek CEO & President, ImprimisRx | Apr 7, 2025 | Tax withholding | −109,475 | $23.09 | $2.53M | 467,388 |
| Andrew R. Boll Chief Financial Officer | Apr 7, 2025 | Tax withholding | −136,745 | $23.09 | $3.16M | 777,844 |
| Mark L. Baum Chief Executive Officer, Director, 10% owner | Apr 7, 2025 | Tax withholding | −300,363 | $23.09 | $6.94M | 2,599,462 |
| John P. Saharek CEO & President, ImprimisRx | Apr 3, 2025 | Option exercise | +277,200 | – | – | 576,863 |
| Andrew R. Boll Chief Financial Officer | Apr 3, 2025 | Option exercise | +346,500 | – | – | 914,589 |
| Mark L. Baum Chief Executive Officer, Director, 10% owner | Apr 3, 2025 | Option exercise | +762,300 | – | – | 2,899,825 |
| Management Inc. Opaleye 10% owner | Mar 24, 2025 | Sale | −5,000 | $30.01 | $150.05K | 140,000 |
| Management Inc. Opaleye 10% owner | Mar 18, 2025 | Sale | −5,000 | $29.64 | $148.20K | 145,000 |
| Management Inc. Opaleye 10% owner | Mar 18, 2025 | Sale | −5,000 | $30.01 | $150.05K | 140,000 |
| Management Inc. Opaleye 10% owner | Mar 18, 2025 | Sale | −5,000 | $29.64 | $148.20K | 145,000 |
| Management Inc. Opaleye 10% owner | Feb 28, 2025 | Sale | −5,000 | $28.05 | $140.25K | 150,000 |
| Management Inc. Opaleye 10% owner | Jan 22, 2025 | Sale | −20,000 | $35.59 | $711.80K | 155,000 |
| John P. Saharek CEO of ImprimisRx | Sep 11, 2024 | Tax withholding | −45,140 | $41.37 | $1.87M | 299,663 |
| John P. Saharek CEO of ImprimisRx | Sep 11, 2024 | Option exercise | +90,000 | $7.37 | $663.30K | 344,803 |
| Management Inc. Opaleye 10% owner | Apr 25, 2024 | Buy | +20,000 | $9.97 | $199.40K | 3,815,000 |
| Management Inc. Opaleye 10% owner | Apr 24, 2024 | Buy | +8,285 | $10.15 | $84.09K | 3,795,000 |
| Management Inc. Opaleye 10% owner | Apr 23, 2024 | Buy | +11,715 | $10.29 | $120.55K | 3,786,715 |
| Management Inc. Opaleye 10% owner | Apr 19, 2024 | Buy | +29,400 | $10.56 | $310.46K | 3,775,000 |
| Management Inc. Opaleye 10% owner | Mar 28, 2024 | Buy | +50,000 | $12.82 | $641.00K | 3,745,600 |
| Mark L. Baum CHIEF EXECUTIVE OFFICER, Director | Mar 22, 2024 | Buy | +9,000 | $11.59 | $104.31K | 2,137,525 |
| Management Inc. Opaleye 10% owner | Mar 20, 2024 | Buy | +50,600 | $9.65 | $488.29K | 3,695,600 |
| John P. Saharek CEO of ImprimisRx | Mar 1, 2024 | Option exercise | +5,000 | $8.75 | $43.75K | 254,803 |
| Andrew R. Boll CHIEF FINANCIAL OFFICER | Feb 20, 2024 | Option exercise | −18,480 | $10.67 | $197.18K | 568,089 |
| Andrew R. Boll CHIEF FINANCIAL OFFICER | Feb 20, 2024 | Option exercise | +45,000 | $10.67 | $480.15K | 586,569 |
| Mark L. Baum CHIEF EXECUTIVE OFFICER, Director | Feb 20, 2024 | Option exercise | +150,000 | $10.67 | $1.60M | 2,188,361 |
| Mark L. Baum CHIEF EXECUTIVE OFFICER, Director | Feb 20, 2024 | Option exercise | −59,836 | $10.67 | $638.45K | 2,128,525 |
| John P. Saharek CEO of ImprimisRx | Feb 20, 2024 | Option exercise | +30,000 | $10.67 | $320.10K | 262,419 |
| John P. Saharek CEO of ImprimisRx | Feb 20, 2024 | Option exercise | −12,616 | $10.67 | $134.61K | 249,803 |
| Andrew R. Boll CHIEF FINANCIAL OFFICER | Feb 7, 2024 | Option exercise | +7,400 | $7.71 | $57.05K | 541,569 |
| Mark L. Baum CHIEF EXECUTIVE OFFICER, Director | Feb 7, 2024 | Option exercise | +15,400 | $7.71 | $118.73K | 2,038,361 |
| Mark L. Baum Chief Executive Officer, Director | Nov 16, 2023 | Buy | +7,500 | $8.11 | $60.82K | 2,022,961 |
| Management Inc. Opaleye 10% owner | Nov 15, 2023 | Buy | +25,000 | $8.03 | $200.75K | 3,645,000 |
| John P. Saharek Chief Commercial Officer | Nov 10, 2023 | Tax withholding | −9,778 | $12.83 | $125.45K | 232,419 |
| John P. Saharek Chief Commercial Officer | Nov 10, 2023 | Option exercise | +20,000 | – | – | 242,197 |
| Management Inc. Opaleye 10% owner | Sep 20, 2023 | Buy | +5,983 | $14.49 | $86.69K | 3,620,000 |
| Management Inc. Opaleye 10% owner | Sep 19, 2023 | Buy | +14,017 | $14.65 | $205.35K | 3,614,017 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Shojaei Amir CHIEF SCIENTIFIC OFFICER | Aug 21, 2026 | 11,250 | $450.00K | Aug 14, 2026 | OPTION EXERCISE |